

Xalkori® (crizotinib) - New formulation approval

- On September 7, 2023, the <u>FDA approved</u> a new oral pellet formulation of Pfizer's <u>Xalkori</u> (crizotinib).
 - Xalkori was previously approved as an oral capsule.
- Xalkori is approved for the treatment of:
 - Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test
 - Pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive
 - Adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor that is ALK-positive.
- Xalkori oral pellets are administered twice daily by one of two options:
 - Open shell(s) containing Xalkori pellets and empty the contents directly into the patient's mouth
 - Open shell(s) containing Xalkori pellets and empty the contents into a consumer -supplied oral dosing aid (eg, spoon, medicine cup). Xalkori pellets should be administered via the dosing aid directly into the patient's mouth.
- Refer to the Xalkori drug label for complete dosing and administration recommendations for oral capsules and pellets.
- Pfizer's launch plans for Xalkori oral pellets are pending. Xalkori oral pellets will be available in 20 mg, 50 mg, and 150 mg strengths.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.